Qiagen NV, the Netherlands-based holding company for the German diagnostics company of the same name, has announced agreements with two US companies for rights to biomarkers that are expected to play a role in the treatment of cancer. ---Subscribe to MedNous to access this article--- Company News Finance, Grants, Deals
